| pubmed-article:16644217 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16644217 | lifeskim:mentions | umls-concept:C0020792 | lld:lifeskim |
| pubmed-article:16644217 | lifeskim:mentions | umls-concept:C0015684 | lld:lifeskim |
| pubmed-article:16644217 | lifeskim:mentions | umls-concept:C0596902 | lld:lifeskim |
| pubmed-article:16644217 | lifeskim:mentions | umls-concept:C1420166 | lld:lifeskim |
| pubmed-article:16644217 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:16644217 | lifeskim:mentions | umls-concept:C1880022 | lld:lifeskim |
| pubmed-article:16644217 | pubmed:issue | 13 | lld:pubmed |
| pubmed-article:16644217 | pubmed:dateCreated | 2006-6-1 | lld:pubmed |
| pubmed-article:16644217 | pubmed:abstractText | Several potent, cell permeable 4-aryl-dihydropyrimidinones have been identified as inhibitors of FATP4. Lipophilic ester substituents at the 5-position and substitution at the para-position (optimal groups being -NO(2) and CF(3)) of the 4-aryl group led to active compounds. In two cases racemates were resolved and the S enantiomers shown to have higher potencies. | lld:pubmed |
| pubmed-article:16644217 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16644217 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16644217 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16644217 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16644217 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16644217 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16644217 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16644217 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:16644217 | pubmed:issn | 0960-894X | lld:pubmed |
| pubmed-article:16644217 | pubmed:author | pubmed-author:RamanPrakashP | lld:pubmed |
| pubmed-article:16644217 | pubmed:author | pubmed-author:SunYingY | lld:pubmed |
| pubmed-article:16644217 | pubmed:author | pubmed-author:CondonStephen... | lld:pubmed |
| pubmed-article:16644217 | pubmed:author | pubmed-author:KaushikVirend... | lld:pubmed |
| pubmed-article:16644217 | pubmed:author | pubmed-author:TumminoPeterP | lld:pubmed |
| pubmed-article:16644217 | pubmed:author | pubmed-author:WuHuiH | lld:pubmed |
| pubmed-article:16644217 | pubmed:author | pubmed-author:BrownJamesJ | lld:pubmed |
| pubmed-article:16644217 | pubmed:author | pubmed-author:HubbardBrianB | lld:pubmed |
| pubmed-article:16644217 | pubmed:author | pubmed-author:YeYingchunY | lld:pubmed |
| pubmed-article:16644217 | pubmed:author | pubmed-author:BalaniSuresh... | lld:pubmed |
| pubmed-article:16644217 | pubmed:author | pubmed-author:TozzoEffieE | lld:pubmed |
| pubmed-article:16644217 | pubmed:author | pubmed-author:GuanBingB | lld:pubmed |
| pubmed-article:16644217 | pubmed:author | pubmed-author:GimenoRuth... | lld:pubmed |
| pubmed-article:16644217 | pubmed:author | pubmed-author:PunreddySandh... | lld:pubmed |
| pubmed-article:16644217 | pubmed:author | pubmed-author:DanielsTomT | lld:pubmed |
| pubmed-article:16644217 | pubmed:author | pubmed-author:BlackburnChri... | lld:pubmed |
| pubmed-article:16644217 | pubmed:author | pubmed-author:CullisCourtne... | lld:pubmed |
| pubmed-article:16644217 | pubmed:author | pubmed-author:JenkinsTracy... | lld:pubmed |
| pubmed-article:16644217 | pubmed:author | pubmed-author:PelusoStephan... | lld:pubmed |
| pubmed-article:16644217 | pubmed:author | pubmed-author:SanchettiPrav... | lld:pubmed |
| pubmed-article:16644217 | pubmed:author | pubmed-author:Yu SunDongD | lld:pubmed |
| pubmed-article:16644217 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16644217 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:16644217 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:16644217 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16644217 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16644217 | pubmed:pagination | 3504-9 | lld:pubmed |
| pubmed-article:16644217 | pubmed:meshHeading | pubmed-meshheading:16644217... | lld:pubmed |
| pubmed-article:16644217 | pubmed:meshHeading | pubmed-meshheading:16644217... | lld:pubmed |
| pubmed-article:16644217 | pubmed:meshHeading | pubmed-meshheading:16644217... | lld:pubmed |
| pubmed-article:16644217 | pubmed:meshHeading | pubmed-meshheading:16644217... | lld:pubmed |
| pubmed-article:16644217 | pubmed:meshHeading | pubmed-meshheading:16644217... | lld:pubmed |
| pubmed-article:16644217 | pubmed:meshHeading | pubmed-meshheading:16644217... | lld:pubmed |
| pubmed-article:16644217 | pubmed:meshHeading | pubmed-meshheading:16644217... | lld:pubmed |
| pubmed-article:16644217 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16644217 | pubmed:articleTitle | Identification and characterization of 4-aryl-3,4-dihydropyrimidin-2(1H)-ones as inhibitors of the fatty acid transporter FATP4. | lld:pubmed |
| pubmed-article:16644217 | pubmed:affiliation | Medicinal Chemistry, Millennium Pharmaceuticals, Inc., 40 Landsdowne St., Cambridge, MA 02139, USA. chris.blackburn@mpi.com | lld:pubmed |
| pubmed-article:16644217 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:16644217 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16644217 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16644217 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16644217 | lld:pubmed |
